PEGylation of therapeutic oligonucletides: From linear to highly branched PEG architectures
Authors:
Open Access
- 6 July 2018
- journal article
- review article
- Published by Tsinghua University Press in Nano Research
- Vol. 11 (10) , 5519-5534
Abstract
PEGylation, the attachment of poly(ethylene glycol) (PEG), has been adopted to improve the pharmacokinetic properties of oligonucleotide therapeutics for nearly 30 years. Prior efforts mainly focused on the investigation of linear or slightly branched PEG having different molecular weights, terminal functional groups, and possible oligonucleotide sites for functionalization. Recent studies on highly branched PEG (including brush, star, and micellar structures) indicate superior properties in several areas including cellular uptake, gene regulation efficacy, reduction of side effects, and biodistribution. This review focuses on comparing the effects of PEG architecture on the physiochemical and biological properties of the PEGylated oligonucleotide.Keywords
This publication has 124 references indexed in Scilit:
- Stabilization and Photochemical Regulation of Antisense Agents through PEGylationBioconjugate Chemistry, 2011
- Core-Clickable PEG-Branch-Azide Bivalent-Bottle-Brush Polymers by ROMP: Grafting-Through and Clicking-ToJournal of the American Chemical Society, 2010
- Functional nanoparticles for molecular imaging guided gene deliveryNano Today, 2010
- Stealth nanoparticles: High density but sheddable PEG is a key for tumor targetingJournal of Controlled Release, 2010
- Aptamers Generated from Cell-SELEX for Molecular Medicine: A Chemical Biology ApproachAccounts of Chemical Research, 2009
- PEG Branched Polymer for Functionalization of Nanomaterials with Ultralong Blood CirculationJournal of the American Chemical Society, 2009
- A combinatorial library of lipid-like materials for delivery of RNAi therapeuticsNature Biotechnology, 2008
- Recognition of Cytosolic DNA Activates an IRF3-Dependent Innate Immune ResponseImmunity, 2006
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- RNA interferenceNature, 2002